Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNA...
Pioneer Group has announced a collaboration agreement with Thermo Fisher Scientific to support biotech founders on their journey towards commerci...
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, c...
Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical needs, announced operational expansion ...
Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...
Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...
Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, a...
" Quotient Sciences, in collaboration with Centillion, has installed the revolutionary Biofoundry-in-a-Box (BiaB™) at its Alnwick site, marking a n...
" Abzena, a leading CDMO/CRO, now offers GMP cell-based potency assays at its UK and US sites, enhancing its support for complex biologics and ADC programs...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with ...
Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...
GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...
- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...
© 2025 Biopharma Boardroom. All Rights Reserved.
